Your Cart
Your cart is empty

Looks like you haven't added any test / checkup to your cart

Add Test / Checkup
User Sign In Health checkup offers
acetone-serum

AML Molecular Prognostication: FLT3, NPM1, and CEBPA

Acute Myeloid Leukemia (AML) is a type of cancer that originates in the bone marrow and quickly affects the blood. It is characterized by the rapid growth of abnormal myeloid cells that interfere with the production of normal blood cells. In AML, mutations in specific genes play a crucial role in the behavior of the disease. The AML Molecular Prognostication panel, which tests for mutations in the FLT3, NPM1, and CEBPA genes, is critical in assessing the prognosis and guiding treatment decisions in AML.


  • Test NameAML Molecular Prognostication: FLT3, NPM1, and CEBPA
  • Sample TypeBone Marrow / Blood
  • Preparations RequiredNo fasting is required for this test. However, it is crucial to inform your doctor about any medications or supplements you are currently taking.
  • Report Time3 days

FLT3 (FMS-like tyrosine kinase 3) gene mutations are among the most common in AML and are often associated with poor prognosis. NPM1 (Nucleophosmin 1) gene mutations, on the other hand, are typically associated with a more favorable prognosis. CEBPA (CCAAT/enhancer-binding protein alpha) mutations can also affect the course of the disease. This panel assesses mutations in all three genes, providing comprehensive genetic information that is vital for AML management.

Home Sample Collection Process

1
Book your convenient slot
Book your convenient slot
2
Sample Collection by Phlebotomist
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
Reporting of the sample at lab
4
Download Reports
Download Reports
Frequently Asked Questions

The AML Molecular Prognostication panel is critical in providing information about the genetic makeup of AML. The presence or absence of mutations in FLT3, NPM1, and CEBPA genes significantly impacts the prognosis and helps in making informed decisions regarding the best treatment strategy.

FLT3 gene mutations are common in AML and result in the activation of FLT3 protein, which can cause the leukemia cells to grow uncontrollably. These mutations are generally associated with an aggressive form of AML and a poor prognosis.

NPM1 mutations are typically associated with a more favorable outcome in AML. They are known to have a distinct pattern of genetic abnormalities and a better response to chemotherapy.

CEBPA mutations can be associated with a favorable prognosis in some cases of AML. However, the presence of other mutations can modify this effect. It's essential to assess CEBPA mutations in the context of other genetic abnormalities.

The sample is usually collected from the blood or bone marrow. The bone marrow sample is typically collected through a bone marrow aspiration procedure.

Normal results would indicate the absence of the specific mutations associated with AML in the FLT3, NPM1, and CEBPA genes. However, the interpretation should be performed by a doctor who will consider the patient's overall clinical picture.

If your test results are abnormal, it's important to consult your doctor to discuss the next steps. Your doctor will interpret the results and may recommend additional testing or treatment options based on the genetic makeup of the AML.

This test is usually done at diagnosis to establish the genetic profile of the AML. It may be repeated during treatment if necessary to monitor the disease, especially if there is a suspected change in the genetic characteristics of the leukemia cells.

No, this test is not used alone for the diagnosis of AML. It is used in conjunction with other tests such as blood counts, bone marrow biopsy, and additional genetic testing to establish an AML diagnosis.

You should consult a hematologist or oncologist if your AML Molecular Prognostication results are abnormal.

Yes, this test can be used to monitor the genetic characteristics of leukemia cells during treatment, which may help in assessing the effectiveness of treatment.

Medications, underlying health conditions, and the technique of sample collection can affect the results of this test.

By identifying the specific mutations present in an individual’s AML cells, the test helps doctors to tailor the treatment plan according to the genetic profile, thereby offering a more targeted and effective treatment approach.

The risks associated with this test are minimal and mainly related to the bone marrow aspiration procedure if performed. These might include pain, infection, or bleeding at the aspiration site.

While lifestyle and environmental factors can play a role in the development of AML, the mutations tested in this panel are generally acquired during a person’s lifetime and are not typically influenced by external factors.

Understanding the genetic makeup of Acute Myeloid Leukemia through the AML Molecular Prognostication panel is critical in predicting the course of the disease and in making informed treatment decisions. This panel, which tests for mutations in FLT3, NPM1, and CEBPA, provides valuable information that can help tailor a personalized treatment plan for patients. It is essential for patients to communicate closely with their doctor to understand the implications of the test results and to participate actively in decision-making for their care.

AML Molecular Prognostication (FLT3+NPM1+CEBPA)
₹ 9900
Schedule Test in Your Available Time
Locations Near You in Hyderabad
  • 4KM from Madhapur
  • 3KM from Banjara Hills
  • 1.9KM from Yusufguda
  • 3KM from Madhura Nagar
  • 5KM from Shaikpet